A steady dysfunctional state caused by chronic antigen stimulation in the tumor
microenvironment (TME) is known as CD8+ T cell exhaustion. Exhausted-like CD8+ T cells …

The management of patients with acute myeloid leukemia (AML) relapsed post allogeneic
hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Intensive …

Recently, CAR-T cell therapy in hematological malignancies has received extensive
attention. The objective of this study is to gain a comprehensive understanding of the current …

Synthesizing clinical evidence largely relies on systematic reviews of clinical trials and
retrospective analyses from medical literature. However, the rapid expansion of publications …

Conventional therapies for acute myeloid leukemia (AML) are characterized by high rates of
relapse, severe toxicities, and poor overall survival rates. Thus, the development of new …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …

Purpose: Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells
and offers novel routes for therapeutic targeting. We used the natural immune receptor TIM-4 …

Numerous cutting-edge immunotherapy approaches have been developed for
hematological malignancies, such as immune-checkpoint inhibitors for lymphomas, chimeric …

Abstract Purpose of Review This review seeks to identify and describe novel genetic and
protein targets and their associated therapeutics currently being used or studied in the …

Chimeric antigen receptor (CAR) T-cell therapy represents one of the most impressive
advances in anticancer therapy of the last decade. While CAR T-cells are gaining ground in …